glp-1 substance use disorder Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine GLP-1 and Substance Use Disorder:
Description
Wharton S, Calanna S, Davies M, et al
The barrier to entry is multi-layered
Whether they will become a sustainable solution or a short-lived trend remains to be seen
Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
doi:10.1016/j.pcl.2024.07.006 CDC
Author contributions QL: Conceptualization, Data curation, Formal analysis, Writing original draft, Writing review & editing
